SARS-CoV-2 (COVID-19)
8
0
0
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (8)
Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants
eVusheld Assessment reaL wORld Effectiveness at UPMC
eVusheld Assessment reaL wORld Effectiveness in the VA Health System
The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers
First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects
Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects
Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood
Rapid Screening Circuit of COVID 19 in Schools, Pilot Study